Saroglitazar cut liver fat in women with PCOS and fatty liver disease

Saroglitazar, a pill that activates two of the body's fat- and sugar-handling switches, reduced liver fat in women who have both polycystic ovary syndrome and fatty liver disease — a small but clean early-stage result in a group that is rarely studied on its own [s1]. The trial is modest in size and short in length, so the right way to read it is as a signal worth chasing, not a verdict.

Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age, and it travels with insulin resistance and excess weight. That combination makes fatty liver disease — now called metabolic dysfunction–associated steatotic liver disease, or MASLD — very common in these women, yet they are consistently under-represented in the trials that test MASLD drugs [s1]. Saroglitazar is a dual agonist of the peroxisome proliferator–activated receptors alpha and gamma, the nuclear switches that help govern how the body burns fat and responds to insulin; the drug is already used for liver and lipid disorders in some countries.

What the trial did

The study was a multicentre, randomised, double-blind, placebo-controlled phase 2A trial [s1]. It enrolled 60 women aged 18 to 45 who had both PCOS and MASLD and assigned them 1:1 to either saroglitazar 4 mg once daily or a matching placebo for 24 weeks [s1]. The main question was how much the drug would shift liver fat, measured with an MRI technique called proton density fat fraction that quantifies the percentage of fat in liver tissue. The primary analysis was done in the per-protocol group — the women who completed the study as designed — which came to 25 on saroglitazar and 23 on placebo [s1].

What it found

Liver fat fell on the drug and barely moved on placebo. The relative change in liver fat content at 24 weeks was −14.81% (plus or minus a standard error of 5.52) with saroglitazar versus +1.96% (plus or minus 5.75) with placebo, a difference that reached statistical significance (p=0.041) [s1]. When the analysts corrected for a chance imbalance in baseline HbA1c — a measure of average blood sugar — between the groups, the gap widened to −18.93% versus +6.43% (p<0.009) [s1].

A second, more demanding yardstick pointed the same way. A 30% or greater reduction in measured liver fat is a threshold many hepatologists treat as clinically meaningful, and more than four times as many women crossed it on the drug: 36.0% of the saroglitazar group versus 8.7% of placebo (p=0.025) [s1]. The drug also significantly lowered liver enzymes (the aminotransferases that signal liver inflammation), improved the lipid profile, and reduced the FibroScan AST score, a composite that estimates liver injury and scarring [s1]. Side effects were comparable between the two groups, none were serious, and one pregnancy that occurred in the saroglitazar arm ended with healthy mother and baby [s1].

How to read it

The strengths here are the design and the endpoint. This was a randomised, double-blind trial with a placebo control, and it measured liver fat directly by MRI rather than relying on a questionnaire or a single blood test — the imaging change is about as objective as a short trial can get [s1]. It also deliberately recruited a population that mainstream MASLD trials tend to skip, which is where its real novelty lies.

The limits are just as plain. Sixty women is small, 24 weeks is short, and the headline result rests on a per-protocol analysis of 48 completers rather than everyone who started [s1]. Liver fat is a surrogate marker: a fall in the fat fraction is encouraging, but it is not the same as preventing the scarring, liver failure, or cardiovascular events that make MASLD dangerous over years. The HbA1c-adjusted figure, while striking, is a secondary calculation prompted by a baseline imbalance, so it is best read as supportive rather than definitive. The authors themselves frame the work as a basis for larger studies [s1]. Related coverage has looked at how common MASLD is and what actually reverses it, semaglutide's effect on liver tissue in the ESSENCE trial, and what the evidence says about managing PCOS.

What to watch

The open questions are the ordinary ones for an early trial: whether the benefit holds in a larger, longer study, whether it translates from a fat measurement into liver tissue and hard outcomes, and how saroglitazar would compare with the GLP-1 drugs and the approved MASLD agents that many of these women might otherwise be offered. For now, the result adds a woman-specific data point to a fast- moving field — and a reminder that a group this common deserves its own evidence.

This article describes research and is not medical advice. Decisions about treating PCOS or fatty liver disease belong with a qualified clinician.